Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 4, Number 4—December 1998

Differentiating Human from Animal Isolates of Cryptosporidium parvum

Article Metrics
citations of this article
EID Journal Metrics on Scopus
Irshad M. Sulaiman, Lihua Xiao, Chunfu Yang, Lilian Escalante, Anne Moore, Charles B. Beard, Michael J. Arrowood, and Altaf A. LalComments to Author 
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Cite This Article


We analyzed 92 Cryptosporidium parvum isolates from humans and animals by a polymerase chain reaction/restriction fragment length polymorphism method based on the thrombospondin-related anonymous protein 2 gene sequence. Used as a molecular marker, this method can differentiate between the two genotypes of C. parvum and elucidate the transmission of infection to humans.

Cryptosporidium parasites cause infection in humans and other vertebrates, including mammals, birds, reptiles, and fish. More than 20 species of Cryptosporidium have been reported, of which six are considered valid species on the basis of oocyst morphologic features and site of infection (1,2). Cryptosporidium parvum, the species that infects humans and most mammals, has a monoxenous life cycle in which all stages of asexual and sexual development occur within one host. The parasite generates large numbers of viable oocysts in feces. Cross-infection studies in various mammalian systems have indicated zoonotic transmission to humans (1,3). C. parvum has caused waterborne outbreaks of cryptosporidiosis and (in AIDS patients) life-threatening diarrhea for which no effective treatment exists (4). A waterborne outbreak of cryptosporidiosis in Milwaukee, Wisconsin, in 1993 affected more than 400,000 people (5).

Molecular characterization techniques used to detect intraspecific variations in C. parvum include isozyme profiles (6); random amplified polymorphic DNA (RAPD) analyses (7); nucleotide sequence studies of the 18S rRNA (8,9) and DHFR gene (10); and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis of the undefined repetitive sequence (11), polythreonine motifs, and oocyst wall protein (12,13). Two distinct genotypes of C. parvum parasites have been detected in humans.

In a previous article, we identified several mutations in the gene thrombospondin-related anonymous protein 2 of C. parvum (TRAP-C2) that differentiate between anthroponotic and zoonotic infection in humans (14). Our objective in the present study was to develop a simple, rapid protocol that can be used as a diagnostic tool to differentiate between the two genotypes of C. parvum and elucidate the transmission of infection in humans. We analyzed 92 C. parvum isolates from humans, calves, deer, dogs, and monkeys and found that this new PCR/RFLP method based on the TRAP-C2 gene sequence can be used as a molecular marker to differentiate between the two genotypes of C. parvum.

Analytic Approach


We summarized data for 92 isolates of C. parvum, 50 from human and 42 from animal sources (Tables 1, 2). Twenty-one of the 50 human isolates were from AIDS patients; the rest were primarily from cryptosporidiosis outbreak case-patients. Seven of the human isolates came from a previous TRAP-C2 sequencing study (14), but because of the lack of DNA, other isolates we used in the previous study were not used in this study. Fecal samples were stored at 4° C in 2.5% potassium dichromate before oocysts were isolated. Oocysts were purified from fecal samples by first using the discontinuous density sucrose gradient centrifugation and then the Percoll gradient centrifugation (15,16).

Extraction of Genomic DNA and PCR Amplification

We followed the protocol of Kim et al. in isolating the total genomic DNA from the purified oocyst (17). A 369 base pair (bp) fragment of the TRAP-C2 gene of C. parvum was amplified by using a forward (cua cua cua cua CAT ATT CCC TGT CCC TTG AG) and a reverse (cau cau cau cau TGG ACA ACC CAA ATG CAG AC) primer (lower case represents nucleotide used for cloning); these primers correspond to positions 848-867 (positive strand) and 1,180-1,199 (negative strand) of the GenBank sequence X77586, respectively. The PCR reaction consisted of 50 ng genomic DNA, 200 μM of each dNTP (Perkin Elmer, Foster City, CA), 40 ng of primer, 1X PCR buffer, and 0.5 units of Taq polymerase (GIBCO BRL, Frederick, MD) in a total volume of 100 μl. DNA amplification was carried out for 35 cycles, each consisting of denaturing (94° C, 45 sec), annealing (48° C, 45 sec), and elongating (72° C, 60 sec), with an initial hot start at 94° C for 5 min in a Perkin Elmer Gene Amp PCR 9600 thermocycler. An additional cycle of 7 min at 72° C was done for final extension. Each experiment used three negative controls (reaction mixtures without Taq polymerase, primers, or template DNA) and a positive control.

DNA Sequencing and Analysis

PCR products were purified by the Wizard PCR Preps DNA purification system (Promega, Madison, WI) and cloned by the CLONEAMP pAMP1 System for Rapid Cloning of Amplification Products (GIBCO BRL, Frederick, MD) according to the manufacturer's protocol. DNA sequencing of recombinant clones that had the correct size insert was carried out on an ABI 377 Automated Sequencer by the dRhodomine Terminator Cycle Sequencing Kit (Perkin Elmer-Applied Biosystems).


To develop an RFLP technique for differentiating between the two genotypes of C. parvum, the TRAP-C2 sequences were aligned and mapped for restriction enzyme sites by the Genetics Computer Group program (18). Enzymes with predicted exclusive cutting in each genotype were used in RFLP development and analysis. For RFLP analysis, 10 μl of amplification products was digested in a 30-μl reaction mix consisting of 10 units of BfaI (New England BioLabs, Beverly, MA), BsetEI (Boehringer Mannheim, Indianapolis, IN), Eco571 (MBI Fermentas, Gariciuno, Vilnius, Lithuania), HaeIII (New England BioLabs), HphI (New England BioLabs), MaeIII (Boehringer Mannheim, Germany), NruI (New England BioLabs), PacI (New England BioLabs), or Tsp45I (New England BioLabs), and 3 μl of respective restriction buffer for 1 hr, under conditions recommended by the supplier. The digested products were fractionated on 2.0% agarose gel and visualized by ethidium bromide staining.


Sequence Analysis of Human and Bovine Isolates

Two genotypes of C. parvum exist in humans,as shown by the primary sequence of the TRAP-C2 gene (14). Nucleotide sequences differed at five positions between most human and bovine isolates. To confirm and extend this observation, we sequenced additional human and bovine isolates, as well as isolates from dogs, deer, and monkeys. We obtained 42 additional sequences of the TRAP-C2 gene from animal sources and 27 additional sequences of the TRAP-C2 gene from human sources; results of DNA sequencing confirmed that C. parvum is highly conserved at the TRAP-C2 locus. All animal isolates, including those from nonbovine animals, showed bovine genotype characteristics (Table 2). Differences between the two genotypes are shown in Table 3. Of the additional 23 human isolates showing human genotype pattern, four isolates (HGMO7, HGMO9, HGMO10, and HNO18) showed "C" at the fifth place, whereas the rest showed "T".

PCR-RFLP Method To Discriminate between Human and Bovine Genotype Isolates


Thumbnail of Human- and bovine-specific restriction enzymes showed distinct banding pattern for genotypes of Cryptosporidium parvum isolates. The different lanes represent the TRAP-C2 PCR-amplified products belonging to AGA43, AMD36, AOH6, HM3, and HM5 isolates of C. parvum, respectively, after digestion with HaeIII (Lanes 1-5, human-specific marker) and BstE II (Lanes 7-11, bovine-specific marker) restriction enzymes and agarose gel electrophoresis. Lane 6 is the 100 bp marker. Samples AGA43, A

Figure. Human- and bovine-specific restriction enzymes showed distinct banding pattern for genotypes of Cryptosporidium parvum isolates. The different lanes represent the TRAP-C2 PCR-amplified products belonging to AGA43, AMD36, AOH6, HM3, and HM5...

To avoid expensive and lengthy DNA sequencing when determining the genotype of C. parvum isolates, we developed a simpler, quicker method—PCR amplification of the TRAP-C2 gene followed by RFLP. Restriction enzyme mapping on the aligned sequences of both genotypes showed five human-genotype–specific (HaeI, HaeIII, NruI, PacI, and ThaI) and six bovine-genotype–specific (BfaI, BsetEI, Eco571, HphI, MaeIII, and Tsp45I) restriction enzymes. All human-genotype– and bovine-genotype–specific restriction enzymes except HaeI and ThaI were tested for the TRAPC-2 PCR-amplified products of genomic DNA of C. parvum. After restriction and gel electrophoresis, the resulting bands were the size predicted by the mapping analysis (Figure). Digestion of PCR products with these enzymes resulted in a distinct band pattern for the human genotype and bovine genotype isolates. In all cases, the DNA sequencing and PCR-RFLP mapping data matched.

Using PCR-RFLP in Outbreak Investigations

We validated the PCR-RFLP technique by using isolates from outbreaks and sporadic cases of human cryptosporidiosis. Human genotype characteristics were evident in all samples from HIV-infected patients from Guatemala and most patients with sporadic clinical cases, as well as samples from the following outbreaks: Milwaukee (1993), Florida (1995), Atlanta (1995), Canada (1995), Nevada (1994), and Washington (1998). Of the 17 samples from HIV-infected patients in New Orleans, two demonstrated bovine-genotype pattern, while the rest were similar to human genotype. However, bovine-genotype characteristics were evident in the human isolates from outbreaks in British Columbia, Canada (1996), Minnesota (1997), and Pennsylvania (1997).


We examined a large number of C. parvum isolates (92) from human and animal sources from patients in outbreak and nonoutbreak settings to determine the two transmission routes of the parasite in humans. Molecular markers were generated by restriction digestion of PCR-amplified TRAP-C2 products with one of the 12 enzymes to differentiate the two genotypes of C. parvum. The results based on TRAP-C2 gene PCR-RFLP showed that this method could also be used in future cryptosporidiosis outbreak investigations.

Results of our characterization of outbreak and nonoutbreak cases of human cryptosporidiosis indicate that anthroponotic organisms account for most cases. We find a large number of human genotype parasites in sporadic cases and in HIV-infected patients. Most cryptosporidiosis outbreaks examined are caused by anthroponotic (human genotype) parasites. Our results suggest similar epidemiologic features of cryptosporidiosis in HIV-infected persons from New Orleans and Guatemala because both were infected with human genotype parasites.

The results of this study confirm the polymorphic nature of C. parvum. As we showed in a previous study, two alleles of the TRAP-C2 gene exist, each representing a distinct genotype of C. parvum with different transmission cycles in humans. The simple PCR-RFLP technique we developed can effectively differentiate between these two genotypes and transmission cycles and can be used as a tool in outbreak investigations of cryptosporidiosis. Information generated from these investigations will be useful not only in identifying the sources of contamination but also in controlling the disease.

Dr. Sulaiman is a postdoctoral research associate in the Molecular Vaccine Section, Division of Parasitic Diseases, National Center for Infectious Diseases, CDC. For the last 7 years, he has focused on the genetic polymorphism of various organisms. He is now conducting molecular typing of Cryptosporidium to understand the transmission routes of the parasite.



We thank Barbara Herwaldt, Corinne S. L. Ong, P. Vijyalakshmi, Bruce Anderson, William Shulaw, A. Morse, and J. Inungu for providing Cryptosporidium isolates.

This work was supported in part by funding from Environmental Protection Agency (DW 75937984-01-1).



  1. O'Donoghue  PJ. Cryptosporidium and cryptosporidiosis in man and animals. Int J Parasitol. 1995;25:13995. DOIPubMedGoogle Scholar
  2. Dubey  JP, Speer  CA, Fayer  R. General biology of Cryptosporidium. Dubey JP, Speer CA, Fayer R, editors. Cryptosporidiosis of man and animals. Boca Raton (FL): CRC Press; 1990. p. 1-29.
  3. Smith  HV. Environmental aspects of Cryptosporidium species: a review. J R Soc Med. 1990;83:62931.PubMedGoogle Scholar
  4. Colford  JM, Tager  IB, Hirozawa  AM, Lemp  GF, Aragon  T, Petersen  C. Cryptosporidiosis among patients infected with human immunodeficiency virus. Am J Epidemiol. 1996;144:80716.PubMedGoogle Scholar
  5. Mac Kenzie  WR, Hoxie  NJ, Proctor  ME, Gradus  MS, Blair  KA, Peterson  DE, A massive outbreak in Milwaukee of Cryptosporidium transmitted through the public water supply. N Engl J Med. 1994;331:1617. DOIPubMedGoogle Scholar
  6. Awad-El-Kariem  FA, Robinson  HA, Dyson  DA, Evans  D, Wright  S, Fox  MT, Differentiation between human and animal strains of Cryptosporidium parvum using isoenzyme typing. Parasitology. 1995;110:12932. DOIPubMedGoogle Scholar
  7. Morgan  UM, Constantine  CC, O'Donoghue  P, Meloni  BP, O'Brien  PA, Thompson  RCA. Molecular characterization of Cryptosporidium isolates from humans and other animals using random amplified polymorphic DNA analysis. Am J Trop Med Hyg. 1996;52:55964.
  8. Carraway  M, Tzipori  S, Widmer  G. Identification of genetic heterogeneity in the Cryptosporidium parvum ribosomal repeat. Appl Environ Microbiol. 1996;62:7126.PubMedGoogle Scholar
  9. Morgan  UM, Constantine  CC, Forbes  DA, Thompson  RCA. Differentiation between human and animal isolates of Cryptosporidium parvum using rDNA sequencing and direct PCR analysis. J Parasitol. 1997;83:82530. DOIPubMedGoogle Scholar
  10. Vasquez  JR, Gooze  L, Kim  K, Gut  J, Petersen  C, Nelson  RG. Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. Mol Biochem Parasitol. 1996;79:15365. DOIPubMedGoogle Scholar
  11. Bonnin  A, Fourmaux  MN, Dubremetz  JF, Nelson  RG, Gobet  P, Harly  G, Genotyping human and bovine isolates of Cryptosporidium parvum by polymerase chain reaction-restriction fragment length polymorphism analysis of a repetitive DNA sequence. FEMS Microbiol Lett. 1996;137:20711. DOIPubMedGoogle Scholar
  12. Carraway  M, Tzipori  S, Widmer  G. A new restriction fragment length polymorphism from Cryptosporidium parvum identifies genetically heterogeneous parasite populations and genotypic changes following transmission from bovine to human hosts. Infect Immun. 1997;65:395860.PubMedGoogle Scholar
  13. Spano  F, Putignani  L, McLauchlin  J, Casemore  DP, Crisanti  A. PCR-RFLP analysis of the Cryptosporidium oocyst wall protein (COWP) gene discriminates between C. wrairi and C. parvum, and between C. parvum isolates of human and animal origin. FEMS Microbiol Lett. 1997;150:20917.PubMedGoogle Scholar
  14. Peng  MP, Xiao  L, Freeman  AR, Arrowood  MJ, Escalante  A, Weltman  AC, Genetic polymorphism among Cryptosporidium parvum isolates supporting two distinct transmission cycles. Emerg Infect Dis. 1997;3:56773. DOIPubMedGoogle Scholar
  15. Arrowood  MJ, Sterling  CR. Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients. J Parasitol. 1987;73:3149. DOIPubMedGoogle Scholar
  16. Arrowood  MJ, Donaldson  K. Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients. J Eukaryot Microbiol. 1996;43:89. DOIPubMedGoogle Scholar
  17. Kim  K, Gooze  L, Petersen  C, Gut  J, Nelson  RG. Isolation, sequence and molecular karyotype analysis of the actin gene of Cryptosporidium parvum. Mol Biochem Parasitol. 1992;50:10514. DOIPubMedGoogle Scholar
  18. Wisconsin Package Version 9.0, Madison (WI): Genetics Computer Group; 1996.




Cite This Article

DOI: 10.3201/eid0404.980424

Table of Contents – Volume 4, Number 4—December 1998

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Altaf A. Lal, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Mail Stop F-12, 4770 Buford Highway, Atlanta, GA 30341-3717, USA; fax: 770-488-4454

Send To

10000 character(s) remaining.


Page created: December 16, 2010
Page updated: December 16, 2010
Page reviewed: December 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.